Document:

Exhibit 10.2

SHAREHOLDER AGREEMENT

Relating to

ASPERA CORP.

(a Delaware corporation)

This Shareholder Agreement (Agreement) is entered into by and among the named Shareholders set forth on Exhibit A, attached hereto and made a part hereof, BioForce Nanosciences, Inc. (BioForce), and Aspera Corp. (Aspera), effective the 11th day of August, 2008 (Effective Date) with respect to the transfer of certain assets to Aspera  by BioForce, the license of certain technology to Aspera by BioForce, and certain related actions and events required and called for in connection therewith.  Each such named individual or entity is hereafter referred to as a Shareholder or Party and together they are the Shareholders or Parties.

In consideration for the promises and obligations herein set forth, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows.

1.  Priority.  Notwithstanding Aspera’s existing Articles of Incorporation or Bylaws, subject only to applicable law, the Parties agree that the provisions set forth herein supersede and shall take precedence over any provisions relating to such matters set forth in any other documents or understandings, and the Parties shall cause all such conflicting documents to be promptly amended or otherwise changed, and take all such other actions referenced or required, in order to fully effect the provisions herein set forth.

2.  Shareholdings.  The share ownership of Aspera at the time of execution of this Agreement is as set forth on Exhibit A.  Aspera hereby represents that it has no existing obligation to issue any additional shares.

3.  Aspera Balance Sheet.  Aspera’s balance sheet as of July 31, 2008 is attached as Exhibit B.  Aspera hereby represents that there have been no material changes to its balance sheet since July 31, 2008.  

4.  Consideration for Shares.  BioForce shall contribute the consideration as and when called for as set forth on Exhibit C and receive therefore the number of shares (Shares) set forth.

5.  Non-Dilution of BioForce Shares.  It is agreed that until such time that Aspera has raised at least $2,000,000 in additional equity capital, BioForce shall receive additional shares whenever Aspera issues shares of its common stock, or equity or debt instruments which are convertible into shares of its common stock, in such number to insure that BioForce’s 19% ownership interest in Aspera is not diluted.  After Aspera has received at least $2,000,000 in additional equity capital, BioForce’s shareholdings will be subject to dilution in the same manner as all other shares of Aspera.  For the avoidance of doubt, if
for example Aspera raises $4 million in additional equity capital, only $2 million of that financing shall dilute BioForce’s equity in Aspera.

-1-

 

 

6.  BioForce Right to Participate in Subsequent Financings.  Aspera agrees to promptly notify BioForce, in writing, of any proposed sale of its equity securities, or any debt securities which are convertible into equity securities.  BioForce shall have the option to participate in any such transaction in the amount which would be necessary in order for it to maintain the same fully-diluted equity ownership in Aspera as it holds immediately prior to the subsequent financing, after taking into account the anti-dilution protection contained in Section 5 hereof.

7.  Board of Directors.  The Shareholders agree that the size of the Board of Directors of the Company (Board) shall be fixed at five (5) and that so long as the following named Shareholders retain their current proportional shareholdings, they shall retain the rights set forth.  BioForce shall have and retain the right to name one (1) director so long as it holds at least fifty percent of the shares being purchased pursuant to this Agreement.  The BioForce director initially shall be Greg Brown.  Shareholders Eric Henderson and Saju Nettikadan, shall also be initial board members.  Kerry Frey shall be added as a board member sixty days after the date of this agreement.  Henderson, Nettikadan and Frey shall be subject to removal from the board by vote of a majority of the Shareholders.  The 5th board member shall be determined in the normal course but shall be a non-Shareholder.  

8.  Stock Option Plan.  It is the intent of the Shareholders that a broad Stock Option Plan (SOP) be adopted by the Company and administered by the Board or such committee thereof as shall be determined by the Board, and that such SOP shall be similar in terms to that in place at BioForce, with which the Parties are familiar, and be available for incentive use with, among others, key employees and non-Shareholder Board members.

9.  Officers.  The officer of the Company is: Saju Nettikadan, President and Chief Science Officer, Kori Radke, Secretary, and Asrun Kristmundsdottir, Treasurer.  

10.  First Right of Refusal.  In the event a Shareholder wishes to sell his/her/its stock  the following provisions shall apply:

a)  The Shareholder shall deliver to the Company written notice stating their intention to sell/transfer the shares, the name of the proposed recipient, the number of shares to be sold/transferred, and the purchase price per share and terms of payment of the proposed sale/transfer. 

b)  The Company shall have 15 days after the receipt of the notice to purchase the shares, upon the price and terms of payment designated in the notice.

c)  If the Company elects not to purchase or obtain the shares, the Shareholders shall have 15 days after the receipt of the notice to purchase the shares, upon the price and terms of payment designated in the notice.

d)  If the Company and the Shareholders elect not to purchase the shares, the Shareholder may sell/transfer the shares to the proposed transferee, on the terms as described in the Shareholder’s notice to the Company, provided that the sale/transfer is completed within 30 days of the expiration of the Shareholders’ right to purchase the shares.

-2-

 

 

e)  Notwithstanding the above, a Shareholder may transfer shares to a member of Shareholder’s immediate family, or to an affiliate company if the Shareholder is a corporate entity, so long as the transferee agrees to be bound by the terms of this Agreement.

11.  Shareholder Ceasing to be an Employee.  In the event that any of the existing shareholders of Aspera (Henderson, Kristmundsdottir, Johnson, Radke, Nettikadan and Mosher) cease to have a relationship with the Company, as either an employee, director or consultant, within twenty-four months of the date of this agreement, the Company shall have the right to purchase a percentage of that individual’s shares for a price equal to the price that the shareholder paid for their shares when issued.  The percentage of shares that the company can buy back will be determined by the length of the individual’s relationship with the company. After two months, the company can buy back 80% of the individual’s shares, with the buyback percentage reduced by 3.64% for each month thereafter. In order to exercise this right, the Company must provide the shareholder with written notice of its intent to do so within 90 days of the cessation of the individual’s relationship with Aspera, and transfer the purchase price to the shareholder within that same 90 day period.  Notwithstanding the above, the Company shall have no rights under this Section 11 once it has a) raised $2 million in equity capital from investors, b) received $1 million from grants which are not being transferred by BioForce as a part of this agreement, or c) achieved an initial public offering of its common stock.  

12.  Related and Dependant Transactions.

12.1  License Agreement.  A License Agreement in the form attached hereto as Exhibit G shall be entered into simultaneously herewith between BioForce and Aspera.

12.2  Transfer of Employees; Release.  The individuals listed on Exhibit D shall be transferred from BioForce to Aspera, as theron set forth and Aspera shall assume all benefit and salary obligations owing thereto, including relating to any vacation accruals, sick pay, and paid time off.  Each of the individuals listed on Exhibit D releases BioForce from all of its obligations to such individuals of any sort arising prior to the date hereof, including without limitation the benefit obligations referred to in the first sentence hereof. 12.3  Sale of Equipment.

i)  BioForce shall sell to Aspera as of August 1, 2008, one Nano eNabler instrument (serial number 4034) for the sum of $30,000. ii)  for the sum of $60,000 BioForce shall sell to Aspera the equipment, as listed on Exhibit E, and provide for Aspera’s use for twenty four months of four PCs currently under lease from Relational, Inc., at the end of which the title to the four PCs will be transferred to Aspera. iii)  The purchase price for the assets sold by BioForce to Aspera in i) and ii) above shall be satisfied by Aspera providing consulting services at no cost to BioForce, as reasonably requested by BioForce but not beyond 24 months from the date hereof, until 1,800 hours have been provided.  These services will be provided at a rate of no more than 100 hours per month and no more than 1,000 hours per twelve month period, with the twelve month periods beginning on August 1, 2008 and 2009.  As of July 31, 2010, if any of the 1,800 hours of no cost consulting services have not been provided to BioForce, Aspera shall issue a
credit memo for the unused hours, at a rate of $50.00 per hour, which BioForce may apply towards any purchase of goods or services from Aspera.

-3-

 

12.4  Transfer of Grants.  BioForce shall work with Aspera to transfer to Aspera as of the date of this Agreement the governmental grants, as shown on Exhibit F so that Aspera may complete the scientific projects that are the subjects of those grants.  Should the providers of the grants not allow them to be transferred to Aspera, BioForce agrees to engage the services of Aspera as a subcontractor under the grants, and pay Aspera for any such subcontractor services a rate equal to the hourly rate of pay of the Aspera employees performing the work, plus an allowance for payroll taxes and employee benefits.

12.5  BioForce Grant Services.  Aspera requires certain microfabrication services to fulfill the requirements of the Microfabricated Deposition Tools grant to be transferred to Aspera as a part of this Agreement, and BioForce has the resources and expertise to perform that work.  Aspera shall purchase contract services from BioForce, in the amount of $70,000, in order to fulfill that microfabrication requirement, at a rate equal to the hourly pay of the BioForce employees performing the work, plus an allowance for payroll taxes and employee benefits.

12.6  Administrative Services.  In transition and start up, BioForce will provide Aspera space and services sharing to commence operations at its facility, at no charge, through August 15, 2008.  It is agreed that Aspera will initiate its operations at a facility other than BioForce’s location no later than August 18, 2008.

13.  Applicable Law, Disputes, and Limitation of Remedies.

13.1  Law and Disputes.  Any controversy or claim arising out of or relating to this Agreement, including its formation, performance, or breach, shall only be resolved in the applicable federal or state courts for Ames, IA.  However, no dispute may be brought by a party more than two years after such party first became aware of the matter.  This Agreement shall be interpreted in accordance with the laws of the State of Iowa, USA, without regard to its conflicts of laws provisions.   

13.2  Limitation on Remedies.  Under no circumstances shall any Party be liable to any other Party by reason of breach of this Agreement for any consequential, general, or special damages even though the Parties may be aware of the possibility of such damages, but any Party may seek injunctive or other immediate relief and pursue specific performance.

14.  Miscellaneous Provisions.

14.1

Independence and Authority.  The Parties hereto are independent contractors solely responsible for their own business operation and compliance obligations.  Each represents to the others full authority to enter into this Agreement and all proper and required authority to perform its obligations hereunder. 

14.2  Severability.  If any provision of this Agreement shall be deemed illegal or unenforceable, such illegality or unenforceability shall not affect the validity and enforceability of any legal and enforceable provisions hereof, this Agreement shall be construed as if such illegal and unenforceable provisions had not been inserted herein, unless such illegality or unenforceability shall destroy the Agreement's underlying business purpose.

 

-4-

  

 

14.3 Assignment.  This Agreement may not be assigned in whole or in part by any Party hereto without the prior written consent of all Parties.

14.4

Entire Agreement.  This Agreement, including the referenced and attached Exhibits, constitutes the entire agreement between the Parties with respect to the matters herein and supersedes all prior understandings and agreements relating to such matters.  No modification of this Agreement will be effective unless in writing signed by all Parties and referencing this Agreement.   

14.5  Non-Recruitment.  BioForce and Aspera agree, during the shareholder relationship at or above this level, not to recruit or hire, without the written approval of the other, any employee or agent acting on behalf of the other except upon payment of one year’s salary of such person as liquidated damages due to the uncertainty and difficulty of estimating loss at this time.

14.6

Notices.  All notices under this Agreement shall be in English and shall be in writing and given by registered airmail, cable, telex (acknowledged by answerback) or facsimile addressed to the parties at the addresses set forth above, or to such other address of which either party may advise the other in writing.  Notices will be deemed given when sent.

14.7

Force Majeure.  No party shall be in default hereunder by reason of any failure or delay in the performance of any obligation under this Agreement where such failure or delay arises out of any cause beyond the reasonable control and without the fault or negligence of such Party.  Such causes shall include, without limitation, storms, floods, other acts of nature, fires, explosions, riots, war or civil disturbance, strikes or other labor unrest, embargoes and other governmental actions or regulations which would prohibit a Party from performing any other aspects of the obligations hereunder, delays in transportation, and liability to obtain necessary labor, supplies or manufacturing facilities.   

14.8  Language.  All documents, reports, notices, and other information required to be provided hereunder, shall be provided in English unless the Parties separately and specifically agree otherwise in writing as an amendment hereto.

14.9  Counterparts. This document may be signed in counterparts and by facsimile, as though simultaneous and as though originals.

 

-5-

  

 

In Witness Whereof, each Party represents that each has carefully reviewed the Agreement and consulted with such experts and advisors as each deemed appropriate.

BioForce Nanosciences, Inc.

 

By /s/ Kery M. Frey_________________________________

     Kerry M. Frey, President and CEO

And /s/ Gregory D. Brown____________________________

       Gregory D. Brown, Exec. VP and CFO 

Aspera Corp.

By /s/ Saju Nettikadan_______________________________

Saju Nettikadan, President

And /s/ Korinna Radke_______________________________

Korinna Radke, Secretary

/s/ Korinna Radke___________________________________

Korinna Radke, an individual

/s/ Eric Henderson___________________________________

Eric Henderson, an individual

/s/ Asrun Kristmundsdottir____________________________

Asrun Kristmundsdottir, an individual

/s/ James Johnson___________________________________

James Johnson, an individual

/s/ Curtis Mosher____________________________________

Curtis Mosher, an individual

/s/ Saju Nettikadan__________________________________

Saju Nettikadan, an individual

-6-

 

Exhibit A

to Shareholders Agreement dated August 11, 2008

relating to Aspera Corp.

Shareholder

Common Shares Owned

Saju Nettikadan

2,000,000

Eric Henderson

1,600,000

Curtis Mosher

1,600,000

Asrun Kristmundsdottir

1,600,000

Kori Radke

1,600,000

James Johnson

1,600,000

Total

10,000,000

-7-

 

Exhibit B

to Shareholders Agreement dated August 11, 2008

relating to Aspera Corp.

Aspera’s July 31, 2008 Balance Sheet

							
	 	 	 	 	

	ASPERA CORP

	 
	 	 	 	 	 	Balance Sheet

	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	July 31, 2008

	ASSETS

	 	 	 	 
	 	Current Assets

	 
	 	 	Stock Subscription Receivable

	100.00 

	TOTAL ASSETS

	 	100.00 

	LIABILITIES & EQUITY

	 
	 	Liabilities

	 	 
	 	 	Current Liabilities

	1,252.07 

	 	Total Liabilities

	1,252.07 

	 	Equity

	 	 	 
	 	 	Common Stock

	100.00 

	 	 	Retained Earnings

	(1,252.07)

	 	Total Equity

	 	(1,152.07)

	TOTAL LIABILITIES & EQUITY

	100.00 

-8-

 

Exhibit C

to Shareholders Agreement dated August 11, 2008

relating to Aspera Corp.

Shares to be Sold to BioForce

2,345,679 shares of Aspera common stock, at a cash price per share of $0.00001, for a total purchase price of $23.46.

 

 

-9-

 

Exhibit D

to Shareholders Agreement dated August 11, 2008

relating to Aspera Corp.

Transferred Employees and Provisions

Note:  Aspera is responsible for the pay for the following employees as of August 1, 2008, thus the accruals below are those on the books of BioForce as of July 31, 2008.

Asrun Kristmundsdottir:

Accrued PTO Hours:  41.03

Accrued Vacation Hours: 0.00

Accrued Sick Hours:  32.05

Saju Nettikadan:

Accrued PTO Hours:  99.31

Accrued Vacation Hours: 0.00

Accrued Sick Hours:  56.00

Kori Radke:

Accrued PTO Hours:  137.20

Accrued Vacation Hours: 0.00

Accrued Sick Hours:  12.00

James Johnson:

Accrued PTO Hours:  170.00

Accrued Vacation Hours: 0.00

Accrued Sick Hours:  48.00

-10-

 

Exhibit E

to Shareholders Agreement dated August 11, 2008

relating to Aspera Corp.

Equipment to be transferred to Aspera

Dimension 3100

Nikon TE 2000U and associated camera and software

One ProCleaner instrument

SMZ Microscope

Nikon TS 100 microscope and associated camera and software

Labconco Horizontal laminar flow hood

-80 C freezer

Water Filtration/distillation system

Autoclave ?

Isotemp Oven

Boekel Shaker

Upright Refrigerator 

Upright Freezer

Microspin (2)

Nanodrop

Analytical balance

Eppendorf  Centrifuge

Laptops – PC Dell Inspiron 630 and Macbook pro (note – laptops used by Curtis and Saju)

One HP Printer (one currently used by Asrun)

Misc Chemical and biomolecules

Misc Labware and furniture

-11-

 

Exhibit F

to Shareholders Agreement dated August 11, 2008

relating to Aspera Corp.

Grants to be transferred to Aspera

CellWell: A Microdevice for Single Cell Analysis, R21 CA133551-01

Microfabricated Deposition Tools for Creating NanoArrays, R44-HG004244-03A1

Biomarker Analysis from Single Cells using Nanobiosensor, R43-GM072146

  -12-

 

 

 

 

 

Exhibit G

to Shareholders Agreement dated August 11, 2008

relating to Aspera Corp.

License Agreement

-13-Exhibit 10.3

EMPLOYMENT AGREEMENT

EMPLOYMENT AGREEMENT (this “Agreement”) effective as of September 1, 2008 between BioForce Nanosciences Holdings, Inc (the “Company”), a Nevada corporation, and Eric R. Henderson (the “Employee”), a resident of the State of Iowa.

WHEREAS, the Company wishes to employ the Employee to render services for the Company on the terms and conditions set forth in this Agreement and the Employee wishes to be retained and employed by the Company on such terms and conditions.

NOW, THEREFORE, in consideration of the premises, the mutual agreements set forth below and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties agree as follows:

1.

Employment.  The Company hereby employs the Employee, and the Employee accepts such employment and agrees to perform services for the Company, for the period and upon the other terms and conditions set forth in this Agreement.

2.

Term.  Unless terminated at an earlier date in accordance with Section 9 of this Agreement, the term of the Employee’s employment hereunder shall be for a period of one year, commencing on September 1, 2008.  This agreement may be renewed for additional one year terms by mutual agreement of the parties.

3.

Position and Duties.  

(a)

Service with Company.  During the term of the Employee’s employment, the Employee agrees to serve as Executive Vice President and Chief Scientific Officer of the Company. The position reports to the President and Chief Executive Officer.  This is a half-time position.

(b)

Performance of Duties.  The Employee agrees to serve the Company faithfully and to the best of his ability during his employment by the Company.  The Employee hereby confirms that he is under no contractual commitments inconsistent with his obligations set forth in this Agreement and that during the term of this Agreement, he will not render or perform services for any other corporation, firm, entity or person which are inconsistent with the provisions of this Agreement, unless agreed to by the Board of Directors.  While he remains employed by the Company, the Employee may participate in reasonable charitable activities, personal business activities and personal investment activities so long as such activities do not interfere with the performance of his obligations under this Agreement. The Company recognizes that the Employee has obligations to Iowa State University in his role as a Professor of Genetics, Development and Cell Biology  and that these obligations do not constitute a conflict with his Company duties.

 

-1-

  

 

 

4.

Compensation.

(a)

Base Salary.  As compensation in full for all services to be rendered by the Employee under this Agreement, the Company shall pay to the Employee a base salary of $100,000 per year, less deductions and withholdings, which salary shall be paid on a semi-monthly basis in arrears in accordance with the Company’s normal payroll procedures and policies.  

(b)

Additional Compensation.  In the course of the employee’s normal activities the employee may achieve key milestones related to, for example, fund raising, patents, sales, and other business goals. At its discretion the Board may award additional compensation for accomplishments of this nature.

(c)

Participation in Benefit Plans.  While he is employed by the Company, the Employee shall also be eligible to participate in all employee benefit plans or programs of the Company to the extent that the Employee meets the requirements for each individual plan. The Company provides no assurance as to the adoption or continuance of any particular employee benefit plan or program, and the Employee’s participation in any such plan or program shall be subject to the provisions, rules and regulations applicable thereto. The costs for participation in such plan by the employee and his family shall be determined in accordance with the Company’s policies, as they may be determined from time to time.  It is understood that Employee shall be a part-time employee during the term of this Agreement, and that his eligibility for participation in employee benefit plans, and costs of participation in those plans, shall be determined on that basis.

(d)

Expenses.  The Company will pay or reimburse the Employee for all reasonable and necessary out-of-pocket expenses incurred by him in the performance of his duties under this Agreement, subject to the Company’s normal policies for expense verification. 

(e)

Vacation.  Employee shall accrue no paid time off during the term of this Agreement.  Further, it is agreed that all accrued vacation time, sick time and paid time off held by Employee as of August 31, 2008 shall be utilized during the term of the Agreement. 

(f)

Deferred Pay.  Employee’s balance of deferred pay as of August 31, 2008 shall be satisfied via the issuance of the Company’s convertible secured promissory notes and warrants on the same terms as the Company’s issuance of the same securities to investors on June 10, 2008 and July 21, 2008.  The Company and Employee will enter into a  Convertible Secured Promissory Note and Warrant Purchase Agreement dated August 31, 2008 to document this transaction.

5.

Confidential Information.  Except as permitted or directed by the Company’s Board of Directors, during the term of his employment or at any time thereafter, the Employee shall not 

 

- 2 -

divulge, furnish or make accessible to anyone or use in any way (other than in the ordinary course of the business of the Company) any confidential or secret knowledge or information of the Company that the Employee has acquired or become acquainted with or will acquire or become acquainted with prior to the termination of the period of his employment by the Company (including employment by the Company or any affiliated companies prior to the date of this Agreement), whether developed by himself or by others, concerning any trade secrets, confidential or secret designs, processes, formulae, plans, devices or material (whether or not patented or patentable) directly useful in any aspect of the business of the Company, any customer or supplier lists of the Company, any confidential or secret development or research work of the Company, or any other confidential information or secret aspects of the business of the Company.  The Employee acknowledges that the above-described knowledge or information constitutes a unique and valuable asset of the Company and represents a substantial investment of time and expense by the Company, and that any disclosure or other use of such knowledge or information other than for the sole benefit of the Company would be wrongful and would cause harm to the Company. Both during and after the term of his employment, the Employee will refrain from any acts or omissions that would reduce the value of such knowledge or information to the Company.  The foregoing obligations of confidentiality shall not apply to any knowledge or information that is now published or which subsequently becomes generally publicly known in the form in which it was obtained from the Company, other than as a direct or indirect result of the breach of this Agreement by the Employee.  

6.

Ventures.  If, during the term of his employment the Employee is engaged in or associated with the planning or implementing of any project, program or venture involving the Company and a third party or parties, all rights in such project, program or venture shall belong to the Company.  Except as approved by the Company’s Board of Directors, the Employee shall not be entitled to any interest in such project, program or venture or to any commission, finder’s fee or other compensation in connection therewith other than the compensation to be paid to the Employee as provided in this Agreement.  Notwithstanding the above, rights in any such project, program or venture involving the Company and either Iowa State University or Aspera Corp. shall be determined by the agreement of those parties.

7.

Non-competition Covenant.

(a)

Agreement Not to Compete.   During the term of his employment with the Company and for a period of one year after the termination of such employment (whether such termination is with or without cause, or whether such termination is occasioned by the Employee or the Company), he shall not directly engage in competition with the Company. 

(b)

Geographic Extent of Covenant. The obligations of the Employee under section 7(a) shall apply to any geographic area in which the Company (i) has engaged in business during the term of this Agreement through production, promotional, sales or marketing activity, or otherwise, or (ii) has otherwise established its goodwill, business reputation or any other customer or supplier relations.

 

- 3 -

 (c)

Limitation of Covenant.  Ownership by the Employee, as a passive investment of less than ten percent of the outstanding shares of capital stock of any corporation listed on a national securities exchange or publicly traded shall not constitute a breach of this Section 7.

(e)

Acknowledgment.  The Employee agrees that the restrictions and agreements contained in this Section 7 are reasonable and necessary to protect the legitimate interests of the Company.

(f)

Blue Pencil Doctrine.  If the duration or geographical extent of, or business activities covered by, this Section 7 are in excess of what is valid and enforceable under applicable law, then such provision shall be construed to cover only that duration, geographical extent or activities that are valid and enforceable. 

8.

Patent and Related Matters.

(a)

Disclosure and Assignment.  The Employee will disclose in writing to the Company complete information concerning each and every invention, discovery, improvement, device, design, apparatus, practice, process, method or product, whether patentable or not, made, developed, perfected, devised, conceived or first reduced to practice by the Employee, either solely or in collaboration with others, during the term of this Agreement relating either directly to the business, products, practices or techniques of the Company, or the Company’s actual or demonstrably anticipated research or development (“Developments”).  The Employee, to the extent that he has the legal right to do so, hereby acknowledges that any and all of the Developments are the property of the Company and hereby assigns and agrees to assign to the Company any and all of the Employee’s right, title and interest in and to any and all of the Developments.   At the request of the Company, the Employee will confer with the Company and its representatives for the purpose of disclosing all Developments to the Company as the Company shall reasonably request during the period of the Employee’s employment with the Company. 

(b)

Limitation on Sections 8.  The provisions of Section 8 shall not apply to any Development meeting the following conditions:

(i)

such Development was developed entirely on the Employee’s own time;

(ii)

such Development does not relate (A) directly to the business of the Company or (B) to the Company’s actual or demonstrably anticipated research or development.

(c)

Assistance of the Employee.  Upon request and without further compensation therefore, but at no expense to the Employee, the Employee will do all lawful acts, including but not limited to, the execution of papers and lawful oaths and the giving of testimony, that in the opinion of the Company, may be necessary or desirable in obtaining, sustaining, reissuing, extending and enforcing United States and foreign copyrights and patents on the Developments, and for perfecting,
affirming and recording the Company’s complete ownership and title thereto, and to cooperate otherwise in all proceedings and matters relating thereto.

 

- 4 -

 

(d)

Records.  The Employee will keep complete, accurate and authentic accounts, notes, data and records of the Developments in the manner and form requested by the Company.  Such accounts, notes, data and records shall be the property of the Company, and, upon its request, the Employee will promptly surrender same to it or, if not previously surrendered upon its request or otherwise, the Employee will surrender the same, and all copies (both electronic and hard copies) thereof, to the Company upon the conclusion of his employment.

(e)

Obligations, Restrictions and Limitations.  The Employee understands that the Company may enter into agreements or arrangements with agencies of the United States Government, and that the Company may be subject to laws and regulations which impose obligations, restrictions and limitations on it with respect to inventions and patents which may be acquired by it or which may be conceived or developed by employees, consultants or other agents rendering services to it.  The Employee shall be bound by all such obligations, restrictions and limitations applicable to any such invention conceived or developed by him while he is employed by the Company and shall take any and all further action which may be required to discharge such obligations and to comply with such restrictions and limitations.

(f)

Copyrightable Material.  All right, title and interest in copyrightable material that the Employee shall conceive or originate, either individually or jointly with others, and which arise out of the performance of this Agreement, will be the property of the Company and are by this Agreement assigned to the Company along with ownership of any and all copyrights in the copyrightable material.  Upon request and without further compensation therefore, but at no expense to the Employee, the Employee shall execute all papers and perform all other acts necessary to assist the Company to obtain and register copyrights on such materials in any and all countries.  Where applicable, works of authorship created by the Employee for the Company in performing his responsibilities under this Agreement shall be considered “works made for hire,” as defined in the U.S. Copyright Act.

(g)

Know-How and Trade Secrets.  All know-how and trade secret information conceived or originated by the Employee that arises out of the performance of his obligations or responsibilities under this Agreement or any related material or information shall be the property of the Company, and all rights therein are by this Agreement assigned to the Company.

9.

Termination of Employment.

(a)

Grounds for Termination.  The Employee’s employment shall terminate prior to the expiration of the initial term set forth in Section 2 or any extension thereof in the event that at any time:

(i)

The Employee dies, 

- 5 -

(ii)

The Employee becomes “disabled,” so that he cannot perform the essential functions of his position with reasonable accommodation, 

(iii)

The Board of Directors of the Company elects to terminate this Agreement for “cause” and notifies the Employee in writing of such election, 

(iv)

The Board of Directors of the Company elects to terminate this Agreement without “cause” and notifies the Employee in writing of such election, or

(v)

The Employee elects to terminate this Agreement and notifies the Company in writing of such election.

If this Agreement is terminated pursuant to clause (i), (ii) or (iii) of this Section 9(a), such termination shall be effective immediately.  If this Agreement is terminated pursuant to clause (iv), or (v) of this Section 9(a), such termination shall be effective 30 days after delivery of the notice of termination.

(b)

“Cause” Defined.  “Cause” means:  

(i)

The Employee has breached the provisions of Section 5, 7 or 8 of this Agreement in any material respect, 

(ii)

The Employee has engaged in willful and material misconduct, including willful and material failure to perform the Employee’s duties as an officer or employee of the Company and has failed to cure such default within 30 days after receipt of written notice of default from the Board of Directors.  

(iii)

The Employee has committed fraud, misappropriation or embezzlement in connection with the Company’s business, or 

(iv)

The Employee has been convicted or has pleaded nolo contendere to serious criminal misconduct (excepting, for example, parking violations and occasional minor traffic violations).

In the event that the Company terminates the Employee’s employment for “cause” pursuant to clause (ii) of this Section 9(b) and the Employee objects in writing to the Board’s determination that there was proper “cause” for such termination within 20 days after the Employee is notified of such termination, the matter shall be resolved by arbitration in accordance with the provisions of Section 10(a).  If the Employee fails to object to any such determination of “cause” in writing within such 20 day period, he shall be deemed to have waived his right to object to that determination.  If such arbitration determines that there was not proper “cause” for termination, such termination shall be deemed to be a termination pursuant to clause (iv) of Section 9(a) and the Employee’s sole remedy shall be to receive the wage continuation benefits contemplated by Section 9(g).

 

- 6 -

(c)

Effect of Termination. Notwithstanding any termination of this Agreement, the Employee, in consideration of his employment hereunder to the date of such termination, shall remain bound by the provisions of this Agreement which specifically relate to periods, activities or obligations upon or subsequent to the termination of the Employee’s employment.

(d)

“Disabled” Defined.  “Disabled” means any mental or physical impairment or disorder that renders the Employee unable to perform the essential functions of his position, with or without reasonable accommodation, for a period of 180 days during any continuous 360-day period.

(e)

Surrender of Records and Property.  Upon termination of his employment with the Company, the Employee shall deliver promptly to the Company all records, manuals, books, blank forms, documents, letters, memoranda, notes, notebooks, reports, data, tables, calculations or copies (both electronic and hard copies) thereof that relate in any way to the business, products, practices or techniques of the Company, and all other property, trade secrets and confidential information of the Company, including, but not limited to, all documents that in whole or in part contain any trade secrets or confidential information of the Company, which in any of these cases are in his possession or under his control.

(f)

Salary Continuation.  If the Employee’s employment by the Company is terminated by the Company pursuant to clause (i), (ii), or (iv) of Section 9(a), the Company shall continue to pay to the Employee (or his heirs in the case of (i)) his base salary (or his heirs in the case of (i)), through August 31, 2009.  If this Agreement is terminated pursuant to clauses (iii) or (v) of Section 9(a), the Employee’s right to base salary and benefits shall immediately terminate, except as may otherwise be required by applicable law. Additional compensation, bonuses and benefits may be approved by the Board of Directors.

10.

Settlement of Disputes.

(a)

Arbitration.  Except as provided in Section 10(b), any claims or disputes of any nature between the Company and the Employee arising from or related to the performance, breach, termination, expiration, application or meaning of this Agreement or any matter relating to the Employee’s employment and the termination of that employment by the Company shall be resolved exclusively by arbitration in Des Moines, Iowa, or in the home state of the Company’s corporate headquarters should the location change during the term of this agreement, in accordance with the applicable rules of the American Arbitration Association.  In the event of submission of any dispute to arbitration, each party shall, not later than 30 days prior to the date set for hearing, provide to the other party and to the arbitrator(s) a copy of all exhibits upon which the party intends to rely at the hearing and a list of all persons each party intends to call at the hearing.  The fees of the arbitrator(s) and other costs incurred by the Employee and the Company in connection with such arbitration shall be paid by each party.  

The decision of the arbitrator(s) shall be final and binding upon both parties.  Judgment of the award rendered by the arbitrator(s) may be entered in any court of competent jurisdiction.  

 

- 7 -

(b)

Venue.  Any action at law, suit in equity or judicial proceeding arising directly, indirectly, or otherwise in connection with, out of, related to or from this Agreement, or any provision hereof, shall be litigated only in the courts of the State of Iowa, located in Story County or in the federal courts located in Des Moines, Iowa or in the home state of the Company’s corporate headquarters should the location change during the term of this agreement.  The Employee and the Company consent to the jurisdiction of such courts over the subject matter set forth in Section 10(b). 

 

11.

Miscellaneous.  

(a)

Entire Agreement.  This Agreement (including the exhibits, schedules and other documents referred to herein) contains the entire understanding between the parties hereto with respect to the subject matter hereof and supersedes any prior understandings, agreements or representations, written or oral, relating to the subject matter hereof.  It is specifically agreed that the Employment Agreement between the Company and Employee, executed as of July 19, 2006 and as amended on July 13, 2007 and January 21, 2008, is no longer in effect as of September 1, 2008.

(b)

Counterparts.  This Agreement may be executed in separate counterparts, each of which will be an original and all of which taken together shall constitute one and the same agreement, and any party hereto may execute this Agreement by signing any such counterpart.

(c)

Severability.  Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable law but if any provision of this Agreement is held to be invalid, illegal or unenforceable under any applicable law or rule, the validity, legality and enforceability of the other provision of this Agreement will not be affected or impaired thereby.  In furtherance and not in limitation of the foregoing, should the duration or geographical extent of, or business activities covered by, any provision of this Agreement be in excess of that which is valid and enforceable under applicable law, then such provision shall be construed to cover only that duration, extent or activities which may validly and enforceably be covered.  

(d)

Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, personal representatives and, to the extent permitted by subsection (e), successors and assigns.  

(e)

Assignability.  Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable (including by operation of law) by either party without the prior written consent of the other party to this Agreement, except that the Company may, without the consent of the Employee, assign its rights and obligations under this Agreement to any corporation, firm or other business entity with or into which the Company may merge or consolidate, or to which the Company may sell or transfer all or substantially all of its assets, or of which 50% or more of the equity investment and of the voting control is owned, directly or indirectly, by, or is under common ownership with, the Company.  After any such assignment by the 

 

- 8 -

Company, the Company shall be discharged from all further liability hereunder and such assignee shall thereafter be deemed to be the Company for the purposes of all provisions of this Agreement including this Section 11.

(f)

Modification, Amendment, Waiver or Termination.  No provision of this Agreement may be modified, amended, waived or terminated except by an instrument in writing signed by the parties to this Agreement.  No course of dealing between the parties will modify, amend, waive or terminate any provision of this Agreement or any rights or obligations of any party under or by reason of this Agreement.  No delay on the part of the Company in exercising any right hereunder shall operate as a waiver of such right.  No waiver, express or implied, by the Company of any right or any breach by the Employee shall constitute a waiver of any other right or breach by the Employee.

(g)

Notices.  All notices, consents, requests, instructions, approvals or other communications provided for herein shall be in writing and delivered by personal delivery, overnight courier, mail, electronic facsimile or e-mail addressed to the receiving party at the address set forth herein.  All such communications shall be effective when received.

 

- 9 -

		
	If to the Company:

Gregory D. Brown

Chief Financial Officer

BioForce Nanosciences, Inc.

1615 Golden Aspen Drive, Ste. 101

Ames, IA  50010

Facsimile:  (515) 233-8337

Email:  gbrown@bioforcenano.com

	If to Employee:

Eric R. Henderson

3725 Mathews Road

            Ames, IA 50014

Email: eric@bumblefunk.com

Any party may change the address set forth above by notice to each other party given as provided herein.

(h)

Headings.  The headings and any table of contents contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.

(i)

Governing Law.  ALL MATTERS RELATING TO THE INTERPRETATION, CONSTRUCTION, VALIDITY AND ENFORCEMENT OF THIS AGREEMENT SHALL BE GOVERNED BY THE INTERNAL LAWS OF THE STATE OF IOWA OR IN THE HOME STATE OF THE COMPANY’S CORPORATE HEADQUARTERS SHOULD THE LOCATION CHANGE DURING THE TERM OF THIS AGREEMENT, WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW PROVISIONS THEREOF.

(j)

Third-Party Benefit.  Nothing in this Agreement, express or implied, is intended to confer upon any other person any rights, remedies, obligations or liabilities of any nature whatsoever.

(k)

Withholding Taxes.  The Company may withhold from any benefits payable under this Agreement all federal, state, city or other taxes as shall be required pursuant to any law or governmental regulation or ruling.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of August 11, 2008. 

BIOFORCE NANOSCIENCES HOLDINGS, INC.

EMPLOYEE

a Nevada corporation

By:/s/ Gregory D. Brown

/s/ Eric R. Henderson

Gregory D. Brown, Exec VP and CFO

Eric R. Henderson

 

- 10 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]